Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
SVB Leerink Presentation Feb 24, 2021
Corporate Deck February 2021
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Press Releases
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
press release
June 10, 2021
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…
Read moreObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
press release
June 2, 2021
– Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an…
Read moreObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
press release
May 31, 2021
Geneva, Switzerland and Boston, MA – May 31, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2021
May 28, 2021
ObsEva Annual General Meeting 2020
June 9, 2020
Upcoming Events
Sorry, there are no events available yes.
Stock Information
Latest Press Release
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
